SEC Comment Letter 0000000000-23-007591 to Poseida Therapeutics, Inc. (CIK 0001661460)
Poseida Therapeutics, Inc. (CIK 0001661460)
Date: July 17, 2023 · CIK: 0001661460 · Accession: 0000000000-23-007591
AI Filing Summary & Sentiment
File numbers found in text: 001-39376
Letter
United States securities and exchange commission logo July 17, 2023 Johanna Mylet Chief Financial Officer Poseida Therapeutics, Inc. 9390 Towne Centre Drive, Suite 200 San Diego, CA 92121 Re:Poseida Therapeutics, Inc. Form 10-K for the fiscal year ended December 31, 2022 Filed March 9, 2023 File No. 001-39376 Dear Johanna Mylet: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
July 17, 2023
Johanna Mylet
Chief Financial Officer
Poseida Therapeutics, Inc.
9390 Towne Centre Drive, Suite 200
San Diego, CA 92121
Re:Poseida Therapeutics, Inc.
Form 10-K for the fiscal year ended December 31, 2022
Filed March 9, 2023
File No. 001-39376
Dear Johanna Mylet:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences